Biologics Market is expected to reach USD 625.6 Billion by the year 2026| Merck & Co. Inc., AbbVie, Inc., AstraZeneca Plc., Amgen, Inc., etc.

According to the current analysis of Reports and Data, the global Biologics market was valued at USD 251.5 Billion in 2018 and is expected to reach USD 625.6 Billion by the year 2026, at a CAGR of 11.9%. The study covers Biologics, a drug that contains living organisms or their specific components or by-products. Biologic medicines are usually injected into the patient's body because of its large molecular size (200-1000x) and fragile molecular structure.

Get a Free Sample PDF Report to understand our report before you purchase: https://www.reportsanddata.com/sample-enquiry-form/2030

Companies considered and profiled in this market study

Merck & Co. Inc., AbbVie, Inc., AstraZeneca Plc., Amgen, Inc., Celgene Corporation, Bristol-Myers Squibb Co., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., GlaxoSmithKline Plc., Novartis AG, Pfizer, Inc., and Novo Nordisk A/S

Parts of organisms like their cells, tissues, recombinant proteins, genes, allergens, blood or blood components, and vaccines are used in biologic drugs. Biologics are used for the treatment of various diseases and conditions like anemia, cancer, and other autoimmune diseases. Biologics are changing the ways doctors treat common conditions that have plagued individuals for years. . Biologics have various potential advantages as they can, theoretically, be customized to hit specific 'gene targets' in the human body

AbbVie's Humira (adalimumab) - a drug used to treat autoimmune disorders such as rheumatoid arthritis. Biologics products including those which are manufactured by biotechnology are heat sensitive and susceptible to contamination. Hence, it is essential to maintain aseptic condition from initial manufacturing process till the end of the production, Biologic drugs have witnessed a significant success rate, notably in cancer and autoimmune diseases. The new developments in the field of immunotherapies, gene and cell therapies, and antibody-drug conjugates, will contribute to the expected growth of biologics in the next upcoming future.

Further key findings from the report suggest

1. Cancer application segment holds a market share of 42.2% followed by autoimmune diseases and infectious diseases holding 35.9% and 14.6% respectively.

2. As of 2018, Monoclonal Antibodies segment dominates the market holding 39.0% of the global market since it is the primary medicine used for the treatment of cancer.

3. On the basis of product type, Gene biologics are growing predominantly with a CAGR of 14.3% followed by vaccines and cellular biologics.

4. On the basis of application, Cancer is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 12.4%.The key factor responsible for the growth of the segment is predominant rise in cancer and geriatric population worldwide.

5. Stringent government regulations and associated side effects like gastrointestinal complications, change in blood pressure, chest pain, breathing problems etc. are the key challenges faced by the Biologics market players.

6. Asia Pacific is expected to account for the 21.4% of the global Biologics market due to the large prevalence of target diseases in countries like India and China.

Ask for available discounts on this report by reaching out to us at @ https://www.reportsanddata.com/discount-enquiry-form/2030

For the purpose of this report, Reports and Data has segmented the Biologics market on the basis of product, application, end use and region:

Product type Outlook (Revenue, USD Million; 2016-2026)

Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular Based Biologics
Gene Based Biologics

Application Outlook (Revenue, USD Million; 2016-2026)

Cancer
Infectious Diseases
Autoimmune diseases
Others

End use Outlook (Revenue, USD Million; 2016-2026)

Hospitals
Clinics
Diagnostic Centers
Others

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Go through our meticulously drafted TOC, Tables, Statistics, Charts, and Company profiles: https://www.reportsanddata.com/report-detail/biologics-market

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports And Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.